{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:41:18Z","timestamp":1773826878515,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.jconrel.2004.01.017","type":"journal-article","created":{"date-parts":[[2004,3,3]],"date-time":"2004-03-03T10:17:38Z","timestamp":1078309058000},"page":"169-178","source":"Crossref","is-referenced-by-count":95,"title":["Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process"],"prefix":"10.1016","volume":"96","author":[{"given":"Jagdish","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Kumar Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorg","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-198611020-00002","article-title":"Clinical pharmacokinetics of cyclosporin","volume":"11","author":"Ptachcinski","year":"1986","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.jconrel.2004.01.017_BIB2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF01046702","article-title":"Intra-individual variability in the relative systemic availability of cyclosporine after oral dosing","volume":"34","author":"Lindholm","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2004.01.017_BIB3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","article-title":"Cyclosporin clinical pharmacokinetics","volume":"24","author":"Fahr","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.jconrel.2004.01.017_BIB4","first-page":"515","article-title":"Insights into chronic cyclosporine nephrotoxicity","volume":"34","author":"Bennett","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2004.01.017_BIB5","first-page":"S27","article-title":"Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration","volume":"56","author":"Jankauskiene","year":"2001","journal-title":"Clin. Nephrol."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1034\/j.1600-0609.2001.t01-1-00440.x","article-title":"Clinical findings and magnetic resonance imaging in severe cyclosporine-related neurotoxicity after allogeneic bone marrow transplantation","volume":"67","author":"Trullemans","year":"2001","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.jconrel.2004.01.017_BIB7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/jlts.2001.27475","article-title":"Neurotoxicity of immunosuppressive drugs","volume":"7","author":"Wijdicks","year":"2001","journal-title":"Liver Transpl."},{"issue":"5","key":"10.1016\/j.jconrel.2004.01.017_BIB8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s004150050360","article-title":"Cyclosporine neurotoxicity: a review","volume":"246","author":"Gijtenbeek","year":"1999","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00007890-198502000-00005","article-title":"Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection","volume":"39","author":"Klintmalm","year":"1985","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.jconrel.2004.01.017_BIB10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/oxfordjournals.ndt.a027620","article-title":"Do cyclosporin profiles provide useful information in the management of renal transplant recipients?","volume":"11","author":"Bowles","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.jconrel.2004.01.017_BIB11","first-page":"3427","article-title":"Neoral\u2014a new microemulsion formula of cyclosporine A: interpatient pharmacokinetic variability in renal transplant recipients","volume":"27","author":"Klauser","year":"1995","journal-title":"Transplant. Proc."},{"issue":"3","key":"10.1016\/j.jconrel.2004.01.017_BIB12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jps.2600830336","article-title":"Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation","volume":"83","author":"Kovarik","year":"1994","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2004.01.017_BIB13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1389200023337630","article-title":"Review: metabolism of immunosuppressant drugs","volume":"3","author":"Kelly","year":"2002","journal-title":"Curr. Drug Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2004.01.017_BIB14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0169-409X(01)00178-8","article-title":"The drug efflux\u2013metabolism alliance: biochemical aspects","volume":"50","author":"Benet","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2004.01.017_BIB15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200241040-00001","article-title":"The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?","volume":"41","author":"Doherty","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.jconrel.2004.01.017_BIB16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/7385","article-title":"Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy","volume":"5","author":"Roy","year":"1999","journal-title":"Nat. Med."},{"issue":"6623","key":"10.1016\/j.jconrel.2004.01.017_BIB17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/386410a0","article-title":"Biologically erodable microspheres as potential oral drug delivery systems","volume":"386","author":"Mathiowitz","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0168-3659(98)00161-8","article-title":"Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice","volume":"58","author":"Chattaraj","year":"1999","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2004.01.017_BIB19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0264-410X(98)00118-2","article-title":"Oral immunization with a Streptococcal pneumoniae polysaccharide conjugate vaccine in enterocoated microparticles induces serum antibodies against type specific polysaccharides","volume":"17","author":"Flanagan","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jconrel.2004.01.017_BIB20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1523-5378.1999.09046.x","article-title":"Oral immunization with Helicobacter pylori-loaded poly (dl-lactide-co-glycolide) nanoparticles","volume":"4","author":"Kim","year":"1999","journal-title":"Helicobacter"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2004.01.017_BIB21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-3659(99)00231-X","article-title":"Oral vaccine delivery","volume":"65","author":"Russell-Jones","year":"2000","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2004.01.017_BIB22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1023\/A:1011063232257","article-title":"Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly (lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice","volume":"18","author":"Jung","year":"2001","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10611869409015904","article-title":"Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particles","volume":"2","author":"Hillery","year":"1994","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2004.01.017_BIB24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0168-3659(90)90133-E","article-title":"Controlled vaccine release in the gut associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches","volume":"11","author":"Eldridge","year":"1990","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2004.01.017_BIB25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.2042-7158.1989.tb06377.x","article-title":"The uptake and translocation of latex nanospheres and microspheres after oral administration to rats","volume":"41","author":"Jani","year":"1989","journal-title":"J. Pharm. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2004.01.017_BIB26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.2042-7158.1990.tb07033.x","article-title":"Nanoparticles uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency","volume":"42","author":"Jani","year":"1990","journal-title":"J. Pharm. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2004.01.017_BIB27","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/jps.1143","article-title":"Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles","volume":"90","author":"Hillyer","year":"2001","journal-title":"J. Pharm. Sci."},{"issue":"25","key":"10.1016\/j.jconrel.2004.01.017_BIB28","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine","volume":"321","author":"Kahan","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2004.01.017_BIB29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-5173(02)00147-3","article-title":"Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution","volume":"242","author":"Chen","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0378-5173(02)00268-5","article-title":"Incorporation of cyclosporin A in solid lipid nanoparticles (SLN)","volume":"241","author":"Ugazio","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2004.01.017_BIB31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of delivery of drugs to the ocular surface. Application of cyclosporine A","volume":"224","author":"De Campos","year":"2001","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2004.01.017_BIB32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0928-0987(00)00198-6","article-title":"Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats","volume":"12","author":"Varela","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0939-6411(00)00143-0","article-title":"Development and characterization of CyA-loaded poly (lactic acid)-poly (ethylene glycol) PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers","volume":"51","author":"Gref","year":"2001","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.jconrel.2004.01.017_BIB34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/026520400417658","article-title":"Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization","volume":"17","author":"Molpeceres","year":"2000","journal-title":"J. Microencapsul."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0378-5173(00)00361-6","article-title":"Studies on cyclosporin A loaded stearic acid nanoparticles","volume":"200","author":"Zhang","year":"2000","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2004.01.017_BIB36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jps.2600820513","article-title":"Formation and characterization of cyclosporine loaded nanoparticles","volume":"82","author":"Guzman","year":"1993","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2004.01.017_BIB37","series-title":"3rd Spanish\u2013Portuguese Conference on Controlled Drug Delivery","first-page":"127","article-title":"Increased oral bioavailability of cyclosporine incorporated in polycaprolactone nanoparticles","author":"Molpeceres","year":"1998"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2004.01.017_BIB38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-5173(02)00461-1","article-title":"Positively charged nanoparticles for improving the oral bioavailability of cyclosporin A","volume":"249","author":"El-Shabouri","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2004.01.017_BIB39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(02)00239-0","article-title":"Investigation of the factors influencing the release rates of cyclosporine A loaded micro- and nanoparticles prepared by high-pressure homogenizer","volume":"84","author":"Lee","year":"2002","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2004.01.017_BIB40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/02652049709006812","article-title":"Optimization of the preparation of loperamide-loaded poly (l-lactide) nanoparticles by high-pressure emulsification-solvent evaporation","volume":"14","author":"Ueda","year":"1997","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2004.01.017_BIB41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0378-5173(87)90146-3","article-title":"Polyalkylcyanoacrylate nanoparticles increase the intestinal absorption of a lipophilic drug","volume":"36","author":"Damge","year":"1987","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2337\/diabetes.37.2.246","article-title":"New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier","volume":"37","author":"Damge","year":"1988","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.jconrel.2004.01.017_BIB43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/jps.2600751009","article-title":"Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles","volume":"75","author":"Maincent","year":"1986","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2004.01.017_BIB44","first-page":"295","article-title":"Pharmacokinetic evaluation of indomethacin nanocapsules","volume":"4","author":"Andrieu","year":"1989","journal-title":"Drug Des. Deliv."},{"key":"10.1016\/j.jconrel.2004.01.017_BIB45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0168-3659(96)01526-X","article-title":"Release of the fluorescent marker Prodan\u00ae from poly (d,l-lactic acid0 nanoparticles coated with albumin or polyvinyl alcohol in model digestive fluids (USP XXII)","volume":"44","author":"Landry","year":"1997","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2004.01.017_BIB46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-3659(02)00127-X","article-title":"Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake","volume":"82","author":"Sahoo","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2004.01.017_BIB47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0927-7757(95)03081-N","article-title":"The colloidal properties of surfactant-free biodegradable nanospheres from poly (\u03b2-malic acid-co-benzyl malate)s and poly (lactic acid-co-glycolide)","volume":"97","author":"Stolnik","year":"1995","journal-title":"Coll. Surf."},{"issue":"5","key":"10.1016\/j.jconrel.2004.01.017_BIB48","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1023\/A:1012117531448","article-title":"Preparation of biodegradable, surface engineered PLGA nanospheres from with enhanced lymphatic drainage and lymph node uptake","volume":"14","author":"Hawley","year":"1997","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2004.01.017_BIB49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1023\/A:1011922819926","article-title":"Stealth PLA-PEG nanoparticles as protein carriers for nasal administration","volume":"15","author":"Tobio","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2004.01.017_BIB50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0169-409X(95)00026-4","article-title":"The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres","volume":"16","author":"Gref","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2004.01.017_BIB51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1097-0126(199904)48:4<251::AID-PI104>3.0.CO;2-4","article-title":"Polyoxyethylene coated nanospheres: effect of coating on zeta potential and phagocytosis","volume":"48","author":"Gref","year":"1999","journal-title":"Polym. Int."},{"issue":"5153","key":"10.1016\/j.jconrel.2004.01.017_BIB52","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1126\/science.8128245","article-title":"Biodegradable long-circulating polymeric nanospheres","volume":"263","author":"Gref","year":"1994","journal-title":"Science"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365904000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365904000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T21:52:28Z","timestamp":1550181148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365904000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0168365904000422"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2004.01.017","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}